CARM (CARISMA Therapeutics) EBITDA Margin %: 96.83% (As of Sep. 2025)


What is CARISMA Therapeutics EBITDA Margin %?

CARISMA Therapeutics CARM +1.25% EBITDA Margin % is 96.83% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, CARISMA Therapeutics ranks better than 85.5% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CARISMA Therapeutics's EBITDA for the three months ended in Sep. 2025 was $43.81 Mil. CARISMA Therapeutics's Revenue for the three months ended in Sep. 2025 was $45.25 Mil. Therefore, CARISMA Therapeutics's EBITDA margin for the quarter that ended in Sep. 2025 was 96.83%.

CARISMA Therapeutics  (OTCPK:CARM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

CARISMA Therapeutics EBITDA Margin % Related Terms

CARISMA Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics EBITDA Margin % Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
0.00 0.00 -571.36 -575.74 -299.64

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -366.53 -470.46 -232.58 0.00 96.83

CARM vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's EBITDA Margin % falls into.


CARISMA Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CARISMA Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-58.825/19.632
=-299.64 %

CARISMA Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=43.814/45.25
=96.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 96.83% mean?
CARISMA Therapeutics (CARM) has a EBITDA Margin % of 96.83% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #137 out of 945 companies in the Biotechnology industry, placing it in the top 14.5%.
Is CARISMA Therapeutics' EBITDA Margin % too high?
CARISMA Therapeutics' current EBITDA Margin % is 96.83%. Based on the distribution chart, CARISMA Therapeutics ranks #137 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CARISMA Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #137 out of 945 companies for EBITDA Margin %. This places CARISMA Therapeutics in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current EBITDA Margin % is 96.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current EBITDA Margin % is 96.83%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current EBITDA Margin % is 96.83% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.